Detection of Hepatoma Serum Marker CD105 with Hemin/Graphene/Aptamer Nanoprobes-Reference-Cited by-同舟云学术

Detection of Hepatoma Serum Marker CD105 with Hemin/Graphene/Aptamer Nanoprobes

Published:2024-03-01 Issue:3 Volume:20 Page:457-466
ISSN:1550-7033
Container-title:Journal of Biomedical Nanotechnology
language:en
Short-container-title:j biomed nanotechnol

Author:

Xia Desong¹,Liu Xiyu¹,Liao Yuhan¹,Wang Huiling¹,Li Yanmei¹,He Jian¹,Zhang Jing¹,Zhong Liping¹,Wang Yuhuan²

Affiliation:

1. State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, 530021, China

2. Shenzhen Hornetcorn Biotechnology Co. Ltd., Shenzhen, 518000, Guangdong, China

Abstract

CD105 is a serum marker of hepatoma. In this study, we established a stable detection platform constructed using a hemin-graphene-aptamer complex (HGN-apt) by optimizing the ratio of graphene, hemin, and aptamer. We also optimized CD105 detection conditions. The detection limit of this platform is 5.5 ng/mL, enabling sensitive detection of CD105. These experiments facilitate an innovative approach for the construction of a detection platform with high sensitivity and an expanded detection range using an HGN-apt probe, enabling specific detection of the serum hepatoma marker CD105. Our findings provide an important foundation for early diagnosis of hepatomas, and would therefore help to alleviate patient suffering, including mental and economic burdens. Our platform also offers a quantitative indicator for the prognosis of hepatomas.

Publisher

American Scientific Publishers

Reference76 articles.